Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
2 hedge funds and large institutions have $38.6K invested in Blueprint Medicines in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
99% less capital invested
Capital invested by funds: $2.57M → $38.6K (-$2.54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KFA
Kelleher Financial Advisors
New York
|
+$38.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$2.57M |
BPMC Hedge Fund Activity: Q1 2026 in Review
2 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2026, worth a combined $38.6K — down 99% from $2.57M a quarter earlier.
Fund positioning in BPMC was balanced in Q1 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Kelleher Financial Advisors, opening a new position worth an estimated $38.5K. The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $2.57M sold.
- 2 institutional investors held Blueprint Medicines (BPMC) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $38.6K of Blueprint Medicines stock for Q1 2026, down 99% quarter-over-quarter.
- 1 fund opened new Blueprint Medicines positions in Q1 2026 and 1 closed out, a net change of 0 holders.
- The largest Blueprint Medicines buyer in Q1 2026 was Kelleher Financial Advisors, an estimated $38.5K added.
- The largest Blueprint Medicines seller in Q1 2026 was DekaBank Deutsche Girozentrale, an estimated $2.57M sold.
Based on aggregated 13F filings for Q1 2026.